Metformin Cost in Maine 2026: Cash Price, Insurance, Medicaid and Compounding

What Does Metformin Actually Cost in Maine Right Now?

Generic metformin is one of the cheapest prescription drugs available in Maine. The average cash-pay price at Maine retail pharmacies sits around $8 per month for a standard 500 mg or 1 to 000 mg twice-daily regimen in 2026, well below the nominal manufacturer list price of roughly $40 per month for the same generic product. GoodRx and similar coupon platforms can push that figure down to $4, $6 per month at high-volume chains such as Walmart, Hannaford Pharmacy, and Rite Aid locations throughout the state.

Prices vary by tablet strength and quantity. A 90-count supply of metformin 500 mg (a common 30-day fill for someone taking two tablets daily) typically runs $8, $12 without insurance. The extended-release formulation, metformin ER (also sold as metformin XR or Glucophage XR generic), costs slightly more, often $12, $18 per month cash, because fewer manufacturers produce it at scale [1].

The FDA approved metformin for type 2 diabetes management in adults and children aged 10 and older, and the current prescribing label permits doses up to 2 to 550 mg daily in adults [2]. Dose affects cost: a patient on 2 to 000 mg per day requires twice the tablet count of someone on 1 to 000 mg, which can double the monthly cash price at some independent pharmacies. Calling ahead for a 90-day supply generally cuts the per-month cost further, sometimes to $5 or less at Costco Maine locations, which do not require a Costco membership to use the pharmacy.

Metformin's low cost is partly a function of its age. The drug has been off patent for decades, and the generic market is deeply competitive. A 2020 analysis in JAMA Internal Medicine confirmed that metformin remained among the 10 least expensive chronic-disease generics in the United States [3].

Does MaineCare (Maine Medicaid) Cover Metformin?

MaineCare covers metformin for eligible members, but prior authorization is required. For members with a documented type 2 diabetes diagnosis, most prior authorization requests are approved quickly, often within one to two business days, provided the prescriber submits a current A1C result and confirms the absence of contraindications such as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² [4].

Prediabetes coverage is more variable. MaineCare does include a Diabetes Prevention Program benefit aligned with the CDC-recognized Diabetes Prevention Program framework, and some members with documented prediabetes (fasting glucose 100 to 125 mg/dL or A1C 5.7 to 6.4%) qualify for metformin coverage under that benefit if lifestyle intervention alone has not achieved target goals [5]. Clinicians submitting PA for prediabetes should document body mass index, duration of lifestyle intervention, and failure to meet an A1C reduction target.

MaineCare members pay $0, $3 in copays for preferred generics on the MaineCare preferred drug list (PDL). Metformin immediate-release is listed as a preferred drug; extended-release formulations may require step therapy through the immediate-release product first [6]. The Maine Department of Health and Human Services updates the PDL quarterly, so prescribers should verify current tier status at the DHHS website before switching a patient to ER formulation.

For members who are dually eligible (Medicare and MaineCare), Medicare Part D covers metformin under most low-income subsidy (LIS/Extra Help) plans at a $0, $4 copay tier, meaning dual-eligible Maine residents typically pay nothing out of pocket [7].

Which Private Insurance Plans Cover Metformin in Maine?

Every ACA-compliant commercial plan sold in Maine covers generic metformin because it meets the preventive-care standard for diabetes management under the ACA's Section 2713, which mandates coverage of USPSTF Grade B recommendations without cost sharing for eligible beneficiaries [8]. Metformin for type 2 diabetes management sits on Tier 1 (preferred generic) of virtually every commercial formulary operating in Maine, including plans offered by Anthem BlueCross BlueShield of Maine, Harvard Pilgrim Health Care, and Community Health Options.

Cost sharing depends on plan design. A standard Tier 1 copay in Maine commercial plans runs $0, $10 per 30-day fill. High-deductible health plans (HDHPs) may require patients to pay full cash price until the deductible is met, which means the $8/month cash figure remains relevant even for insured Maine residents on HDHPs before January 1 resets.

Employer self-insured plans are governed by ERISA and are not required to mirror ACA formulary rules. However, nearly all major self-insured Maine employers include metformin on Tier 1 by default because it reduces downstream diabetes-complication costs. A 2019 health economic model published in Diabetes Care estimated that widespread metformin use in prediabetes could prevent 620,000 cases of type 2 diabetes over 10 years in the United States, generating substantial insurer savings [9].

Medicare Part D plans sold in Maine place metformin on Tier 1 or Tier 2 of standard formularies. The 2026 Medicare Part D out-of-pocket cap of $2,000 has minimal practical effect on metformin because most Part D enrollees pay $0, $7 per month for this drug long before any cap is relevant [10].

Is Compounded Metformin Legal in Maine?

Compounded metformin is legal in Maine when dispensed by a state-licensed 503A compounding pharmacy operating under a valid prescription for an identified patient. Maine follows federal 503A standards under the Drug Quality and Security Act, which permit pharmacies to compound commercially available drugs for individual patients when there is a legitimate clinical rationale, such as an allergy to a tablet excipient or a need for a liquid formulation for a patient with swallowing difficulty [11].

A 503A pharmacy in Maine cannot compound metformin in bulk for office use or for general distribution without a patient-specific prescription. That boundary is firm under both federal law and Maine Board of Pharmacy rules [12]. Some telehealth platforms advertise "compounded metformin" as a way to supply the drug at low or no cost, using charitable patient assistance structures or manufacturer-funded programs. Those arrangements are legal only when the compounding pharmacy holds a current Maine license and the prescription is individualized.

Cost for compounded metformin through these programs can reach $0 per month for qualifying patients, compared with the $8 average for retail generic. The savings are real but come with caveats: compounded products are not FDA-approved, batch consistency is not subject to the same manufacturing standards as commercially produced generics, and the treating clinician should document the medical rationale for compounding in the patient chart [13].

Patients in rural Maine, where the nearest retail pharmacy may be 30 to 60 minutes away, sometimes benefit most from compounding pharmacy mail delivery. Several licensed 503A pharmacies serving Maine residents ship within 48 hours of prescription receipt, making access comparable to urban pharmacy availability.

Can Maine Residents Get Metformin Through Telehealth?

Yes. Maine law permits telehealth prescribing of metformin for both type 2 diabetes and prediabetes without an in-person visit, provided the prescriber conducts a synchronous audio-visual evaluation sufficient to establish a valid patient-provider relationship [14]. Audio-only (phone-only) telehealth encounters may satisfy this requirement in Maine under continuing flexibilities extended after the COVID-19 public health emergency, but prescribers should confirm current state telehealth rules with the Maine Board of Licensure in Medicine before relying solely on phone visits.

From a practical standpoint, a telehealth visit for metformin in Maine typically involves: a review of recent lab work (A1C, basic metabolic panel to assess renal function, and a fasting lipid panel), a medication history, and a discussion of contraindications. The FDA label contraindicates metformin in patients with an eGFR below 30 mL/min/1.73 m² and recommends reassessment if eGFR falls between 30 and 45 mL/min/1.73 m² [2]. Telehealth prescribers must confirm renal function before initiating, which means recent lab results are generally required prior to the visit.

HealthRX clinicians licensed in Maine can prescribe metformin through our platform. After prescription issuance, patients can route the prescription to any Maine retail pharmacy for the standard $8 cash price, use a GoodRx coupon for potentially lower pricing, or request routing to a licensed 503A compounding pharmacy if there is a documented clinical reason for compounding.

The UKPDS 34 trial (N=1,704 overweight patients with newly diagnosed type 2 diabetes) published in The Lancet in 1998 remains the foundational evidence for metformin. Patients randomized to metformin showed a 36% reduction in all-cause mortality and a 39% reduction in myocardial infarction compared with conventional diet-only therapy, effects not seen with sulfonylureas or insulin in the same trial population [15]. That evidence base supports prescribing metformin as first-line therapy across care settings, including telehealth.

What Are the Cheapest Ways to Get Metformin in Maine in 2026?

The four lowest-cost options for Maine residents, ranked by typical monthly out-of-pocket cost, are below.

Option 1: Retail generic with a coupon. GoodRx, RxSaver, and NeedyMeds all offer free coupons accepted at Maine pharmacies. Presenting a coupon at Walmart Pharmacy on Outer Congress Street in Portland or at Hannaford locations statewide can bring a 60-tablet supply of metformin 500 mg to $4, $6. No insurance card is needed and the coupon applies immediately [16].

Option 2: Costco Pharmacy (no membership required). Costco Pharmacy in South Portland prices metformin 500 mg (180 tablets, a standard 90-day supply for twice-daily dosing) at approximately $7, $9 without a coupon. Members and non-members pay the same price [17].

Option 3: Maine community health center sliding-scale programs. Federally Qualified Health Centers (FQHCs) operating in Maine, including Penobscot Community Health Care and Community Health and Counseling Services, participate in the 340B Drug Pricing Program. Under 340B, eligible patients receive metformin at or near cost, which may be $1, $3 per month or free for uninsured low-income patients [18].

Option 4: Licensed 503A compounding with patient assistance. Certain telehealth platforms structure compounded metformin programs so that cost to the patient is $0 through charitable or manufacturer-assistance funding. Legal when properly structured, as described in the compounding section above.

The table below summarizes cost by pathway for a typical Maine patient taking metformin 1 to 000 mg twice daily (a common maintenance dose):

| Pathway | Estimated Monthly Cost (2026) | |---|---| | Cash pay, retail pharmacy, no coupon | ~$8 | | Retail pharmacy with GoodRx coupon | $4, $6 | | Costco Pharmacy (90-day supply) | ~$7, $9 (per month equivalent) | | MaineCare (Medicaid, preferred generic tier) | $0, $3 copay | | Medicare Part D (Tier 1, standard plan) | $0, $7 | | FQHC / 340B program | $0, $3 | | Licensed 503A compounding with assistance program | $0 |

Clinical Monitoring Requirements Maine Prescribers Follow

Getting metformin is step one. Staying on it safely requires periodic monitoring regardless of where or how it was prescribed. The American Diabetes Association 2024 Standards of Care recommend checking renal function (eGFR and serum creatinine) at baseline, 3 to 6 months after initiation, and annually thereafter in stable patients [19]. If eGFR drops to 30 to 44 mL/min/1.73 m², the prescriber should reassess dose and document the risk-benefit decision. If eGFR falls below 30, metformin must be stopped [2].

Vitamin B12 deficiency is an underappreciated long-term risk. A randomized trial (N=390) published in the BMJ demonstrated that metformin use for 4.3 years reduced serum B12 by a mean of 19% compared with placebo (P<0.001), with 7.2% of metformin patients developing frank deficiency [20]. The ADA recommends periodic B12 measurement in patients on long-term metformin, particularly those with peripheral neuropathy or anemia [19].

Gastrointestinal side effects, including nausea, diarrhea, and abdominal discomfort, affect roughly 25 to 30% of patients starting immediate-release metformin [21]. Titrating slowly from 500 mg once daily with dinner, then increasing by 500 mg per week to the target dose, reduces discontinuation rates. Extended-release formulations cause significantly fewer GI side effects in head-to-head comparisons, which is the primary clinical rationale for choosing metformin ER despite its modestly higher cost [22].

Metformin Beyond Type 2 Diabetes: What Maine Prescribers Are Ordering

Maine clinicians prescribe metformin off-label for several conditions beyond type 2 diabetes. The evidence base varies in quality.

Prediabetes is the strongest off-label indication. The Diabetes Prevention Program (DPP) trial (N=3,234) found that metformin 850 mg twice daily reduced progression from prediabetes to type 2 diabetes by 31% over 2.8 years, compared with 58% for intensive lifestyle intervention [23]. The ADA now lists metformin as an option for high-risk prediabetes patients, particularly those with BMI above 35 kg/m² or a history of gestational diabetes [19].

Polycystic ovary syndrome (PCOS) is another common off-label use. A Cochrane review of 44 trials found that metformin improved ovulation rates and menstrual regularity in women with PCOS, though it performed less well than letrozole for ovulation induction in women seeking pregnancy [24]. Maine OB-GYN and endocrinology practices prescribe metformin for PCOS management under shared decision-making with patients.

Longevity and anti-aging research represents a newer and more speculative area. The TAME (Targeting Aging with Metformin) trial, a six-year multicenter randomized controlled trial funded by the American Federation for Aging Research, is currently enrolling adults aged 65, 79 with age-related conditions to test whether metformin 1 to 500 mg daily delays the onset of new age-related diseases [25]. Results are not yet available, and metformin should not be prescribed for longevity as a primary indication outside a clinical trial.

Weight loss is sometimes cited, but the evidence is modest. A meta-analysis of 23 trials published in Obesity Reviews found that metformin produced a mean weight reduction of 1.9 kg versus placebo in non-diabetic overweight adults, far below the 15% body weight reduction seen with semaglutide 2.4 mg in STEP-1 (N=1,961 to 68 weeks) [26, 27]. Maine prescribers should set realistic expectations when patients ask about metformin for weight management.

How Maine Compares to Other New England States on Metformin Access

Maine's average cash price of $8 per month is consistent with the broader New England region, where retail generic metformin ranges from $6 to $12 depending on pharmacy chain and coupon availability. Maine's rural geography creates a distributional access problem that pure price comparisons miss: roughly 38% of Maine residents live in rural areas, compared with a U.S. average of 14%, according to U.S. Census Bureau data [28]. Rural patients face longer travel times to retail pharmacies, making mail-order and telehealth-plus-mail-delivery more relevant here than in more urbanized states.

MaineCare's prior authorization requirement for metformin is stricter than neighboring New Hampshire (no PA required for Medicaid enrollees) but comparable to Vermont Medicaid, which also requires PA for non-insulin diabetes drugs [6]. Maine advocates have periodically pushed for PA removal given metformin's cost, safety profile, and decades of evidence, but the requirement remained in place as of the January 2025 PDL update.

The Maine Quality Counts initiative, a statewide health quality collaborative, reported in its 2023 primary care scorecard that 68% of Maine adults with type 2 diabetes were at A1C goal (<7%), below the national average of 73% [29]. Access barriers, including insurance gaps and rural pharmacy distance, are cited as contributing factors. Improving metformin affordability and telehealth access may help close that gap.